Psychiatrienet - User contributions [en]

User talk:Klaas

2010-03-10T20:23:53Z

Klaas: /* templates */

{{welkom}}

Hallo Klaas, de grafieken van paliperidone_LA kun je niet verantwoorden, omdat je de kinetiek niet kent. Verander nog maar niets, omdat ik de kinetiek bij JC opgevraagd heb. gr Walter

== CombiningMoodstabilizers ==
Hallo Klaas,

Zie [[CombiningMoodstabilizers]] voor een eerste opzet met alle links nog rood...
Ik heb de hier benodigde info al van de testwiki gekopieerd.
In de kruistabel staan nu waarschijnlijk een hele serie onzinnige combinaties. Daar doen we later nog iets aan. Nu gaat het er vooral om eerst de ''wel'' zinvolle combinaties te beschrijven. - [[User:Musys|Arent]] 17:03, 1 March 2010 (CET)

== [[Combining-Carbamazepine-Lamotrigine]] ==
Ik heb net de pagina aangepast; een paar kleine geitjes:
*Het gebruiken van hoofdstukindeling in een sjablooninvulling geeft problemen.
*Harde regelovergangen in een referentietekst zijn ook niet probleemloos

Ik zie een paar methodologische valkuilen.
* de metabolisatiegegevens zouden onderdeel moeten zijn van de medicamentpagina's om te voorkomen dat je deze informatie op alle combinatiepagina's moet gaan herhalen (onderhoud!)
* ga je onderscheid maken tussen het toevoegen van [[Combining-Carbamazepine-Lamotrigine|lamotrigine aan carbamazepine]] versus het toevoegen van [[Combining-Lamotrigine-Carbamazepine|carbamazepine aan lamotrigine]]?
- [[User:Musys|Arent]] 16:28, 3 March 2010 (CET)

Bedankt voor de snelle reactie. Enkele antwoorden:
* De metabolisatiegegevens zijn vaste gegevens; daar zal niet snel meer iets aan veranderen. Is het dan nog steeds onderhoudsintensief?
* Er wordt inderdaad onderscheid gemaakt tussen carba+lamo en lamo+carba. Er zullen dus andere teksten op de pagina’s komen.
[[User:Klaas|Klaas]] 16:41, 3 March 2010 (CET)

== templates ==
Hoi Klaas, even een paar puntjes nu je de tabel aan het vullen bent.
* Klopt het dat [[Gabapentine]] en [[Ziprasidone]] uit de tabel kunnen?
* Ik heb net voor een aantal steeds terugkomende zinsneden templates gemaakt.
* de metabolisatiebeschrijving van de middelen horen op de betreffende pagina. Ik moet het nog zo organiseren dat ze dan automatiek op de combi-pagina's verschijnen.
* Kun je kleine letters gebruiken in "add = " en "base = " dan komen de categorieën ook meteen goed.
* In je brontekst staan een paar spelfoutjes die nu iedere keer ingevoerd worden ;-)
** inhibit'''e'''r
** lamo'''p'''trigine
Suc6 ! - [[User:Musys|Arent]] 09:49, 5 March 2010 (CET)

:: Zo te zien is ie bijna compleet als het klopt dat [[ziprasidone]] uit de tabel kan...
:: Welterusten ;-) - [[User:Musys|Arent]] 00:15, 10 March 2010 (CET)

Beste Arent,
Ik heb gisteren inderdaad de tabel afgemaakt. De ziprasidone heeft momenteel (nog) geen plaats in de therapie en kan uit de tabel (is reeds gebeurd). Mijn stageperiode zit er op na het afronden van de tabel met mood stabilizers. Bedankt voor de technische ondersteuning en succes met het uitbreiden en onderhouden van de tabellen!
Groeten Klaas
[[User:Klaas|Klaas]] 21:23, 10 March 2010 (CET)

Combining-Gabapentin-Topiramate

2010-03-09T23:13:05Z

Klaas: Created page with '{{Drugcombi | base = gabapentin | add = topiramate | info = * Gabapentine is eliminated unchanged by the kidney for 100%. Changes in the rate of excretion can cause unwanted eff...'

{{Drugcombi
| base = gabapentin
| add = topiramate
| info =
* Gabapentine is eliminated unchanged by the kidney for 100%. Changes in the rate of excretion can cause unwanted effects.
* Topiramate induces CYP3A4 and is an inhibiter of CYP2C19.
* This combination of drugs may have possible synergistic effects. There are no reports for pharmacokinetic drug interactions. However, the combination will have additional side effects.
| start =
* Start topiramate according to the general dosing advice.
| cave =
}}

Combining-Topiramate-Gabapentin

2010-03-09T23:12:26Z

Klaas:

{{Drugcombi
| base = topiramate
| add = gabapentin
| info =
* Topiramate induces CYP3A4 and is an inhibiter of CYP2C19.
* Gabapentine is eliminated unchanged by the kidney for 100%. Changes in the rate of excretion can cause unwanted effects.
* This combination of drugs may have possible synergistic effects. There are no reports for pharmacokinetic drug interactions. However, the combination will have additional side effects.
| start =
* Start gabapentin according to the general dosing advice.
| cave =
}}

Combining-Topiramate-Gabapentin

2010-03-09T23:12:07Z

Klaas: Created page with '{{Drugcombi | base = topiramate | add = gabapentin | info = * Topiramate induces CYP3A4 and is an inhibiter of CYP2C19. * Gabapentine is eliminated unchanged by the kidney for ...'

{{Drugcombi
| base = topiramate
| add = gabapentin
| info =
* Topiramate induces CYP3A4 and is an inhibiter of CYP2C19.
* Gabapentine is eliminated unchanged by the kidney for 100%. Changes in the rate of excretion can cause unwanted effects.
* This combination of drugs may have possible synergistic effects. There are no reports for pharmacokinetic drug interactions. However, the combination will have additional side effects.
| start =
* Start topiramate according to the general dosing advice.
| cave =
}}

Combining-Gabapentin-Lamotrigine

2010-03-09T23:09:57Z

Klaas: Created page with '{{Drugcombi | base = gabapentin | add = lamotrigine | info = * Gabapentine is eliminated unchanged by the kidney for 100%. Changes in the rate of excretion can cause unwanted ef...'

{{Drugcombi
| base = gabapentin
| add = lamotrigine
| info =
* Gabapentine is eliminated unchanged by the kidney for 100%. Changes in the rate of excretion can cause unwanted effects.
* Lamotrigine is principally metabolised by UDP-glucuronosyltransferases.
* This combination of drugs may have possible synergistic effects. There are no reports for pharmacokinetic drug interactions. However, the combination will have additional side effects.
| start =
* Start lamotrigine according to the general dosing advice.
| cave =
}}

Combining-Lamotrigine-Gabapentin

2010-03-09T23:08:59Z

Klaas: Created page with '{{Drugcombi | base = lamotrigine | add = gabapentin | info = * Lamotrigine is principally metabolised by UDP-glucuronosyltransferases. * Gabapentine is eliminated unchanged by ...'

{{Drugcombi
| base = lamotrigine
| add = gabapentin
| info =
* Lamotrigine is principally metabolised by UDP-glucuronosyltransferases.
* Gabapentine is eliminated unchanged by the kidney for 100%. Changes in the rate of excretion can cause unwanted effects.
* This combination of drugs may have possible synergistic effects. There are no reports for pharmacokinetic drug interactions. However, the combination will have additional side effects.
| start =
* Start gabapentin according to the general dosing advice.
| cave =
}}

Combining-Gabapentin-Quetiapine

2010-03-09T23:07:28Z

Klaas:

{{Drugcombi
| base = gabapentin
| add = quetiapine
| info =
* Gabapentine is eliminated unchanged by the kidney for 100%.
* Quetiapine is principally metabolized by CYP3A4 to active and inactive metabolites.
* This combination of drugs may have possible synergistic effects. There are no reports for pharmacokinetic drug interactions. However, the combination will have additional side effects.
| start =
* Start quetiapine according to the general dosing advice.
| cave =
* Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects. <ref name="drugscom">
{{Drugscominteract|quetiapine-with-gabapentin-1147-0-1979-1274|quetiapine|gabapentin}}</ref>
}}

Combining-Gabapentin-Olanzapine

2010-03-09T23:07:17Z

Klaas:

{{Drugcombi
| base = gabapentin
| add = olanzapine
| info =
* Gabapentine is eliminated unchanged by the kidney for 100%.
* Olanzapine is principally metabolized by CYP1A2 and CYP2D6.
* This combination of drugs may have possible synergistic effects. There are no reports for pharmacokinetic drug interactions. However, the combination will have additional side effects.
| start =
* Start olanzapine according to the general dosing advice.
| cave =
* Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects. <ref name="drugscom">
{{Drugscominteract|olanzapine-with-gabapentin-1147-0-1744-1113|olanzapine|gabapentin}}</ref>
}}

Combining-Gabapentin-Risperidone

2010-03-09T23:07:05Z

Klaas:

{{Drugcombi
| base = gabapentin
| add = risperidone
| info =
* Gabapentine is eliminated unchanged by the kidney for 100%.
* Risperidone is principally metabolized by CYP2D6 to an active metabolite.
* This combination of drugs may have possible synergistic effects. There are no reports for pharmacokinetic drug interactions. However, the combination will have additional side effects.
| start =
* Start risperidone according to the general dosing advice.
| cave =
* Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects. <ref name="drugscom">
{{Drugscominteract|risperidone-with-gabapentin|risperidone|gabapentin}}</ref>
}}

Combining-Quetiapine-Gabapentin

2010-03-09T23:06:51Z

Klaas:

{{Drugcombi
| base = quetiapine
| add = gabapentin
| info =
* Quetiapine is principally metabolized by CYP3A4 to active and inactive metabolites.
* Gabapentine is eliminated unchanged by the kidney for 100%.
* This combination of drugs may have possible synergistic effects. There are no reports for pharmacokinetic drug interactions. However, the combination will have additional side effects.
| start =
* Start gabapentine according to the general dosing advice.
| cave =
* Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects. <ref name="drugscom">
{{Drugscominteract|quetiapine-with-gabapentin-1147-0-1979-1274|quetiapine|gabapentin}}</ref>
}}

Combining-Olanzapine-Gabapentin

2010-03-09T23:06:37Z

Klaas:

{{Drugcombi
| base = olanzapine
| add = gabapentin
| info =
* Olanzapine is principally metabolized by CYP1A2 and CYP2D6.
* Gabapentine is eliminated unchanged by the kidney for 100%.
* This combination of drugs may have possible synergistic effects. There are no reports for pharmacokinetic drug interactions. However, the combination will have additional side effects.
| start =
* Start gabapentine according to the general dosing advice.
| cave =
* Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects. <ref name="drugscom">
{{Drugscominteract|olanzapine-with-gabapentin-1147-0-1744-1113|olanzapine|gabapentin}}</ref>
}}

Combining-Risperidone-Gabapentin

2010-03-09T23:06:24Z

Klaas:

{{Drugcombi
| base = risperidone
| add = gabapentin
| info =
* Risperidone is principally metabolized by CYP2D6 to an active metabolite.
* Gabapentine is eliminated unchanged by the kidney for 100%.
* This combination of drugs may have possible synergistic effects. There are no reports for pharmacokinetic drug interactions. However, the combination will have additional side effects.
| start =
* Start gabapentine according to the general dosing advice.
| cave =
* Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects. <ref name="drugscom">
{{Drugscominteract|risperidone-with-gabapentin|risperidone|gabapentin}}</ref>
}}

Combining-Gabapentin-Lithium

2010-03-09T23:06:07Z

Klaas: Created page with '{{Drugcombi | base = gabapentin | add = lithium | info = * Gabapentine is eliminated unchanged by the kidney for 100%. * Lithium is eliminated by the kidney for about 95%. Chang...'

{{Drugcombi
| base = gabapentin
| add = lithium
| info =
* Gabapentine is eliminated unchanged by the kidney for 100%.
* Lithium is eliminated by the kidney for about 95%. Changes in the rate of excretion can cause unwanted effects.
* This combination of drugs may have possible synergistic effects. There are no reports for pharmacokinetic drug interactions. However, the combination will have additional side effects. <ref name=”freeman”> {{Pubmed|9433333|Freeman et al. Mood stabilizer Combinations: A Review of Safety and Efficacy. Am J Psychiatry 1998;155:12-21}}</ref>
| start =
* Start lithium according to the general dosing advice.
| cave =
* Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects. <ref name="drugscom">
{{Drugscominteract|lithium-with-gabapentin|lithium|gabapentin}}</ref>
}}

Combining-Lithium-Gabapentin

2010-03-09T23:04:37Z

Klaas: Created page with '{{Drugcombi | base = lithium | add = gabapentin | info = * Lithium is eliminated by the kidney for about 95%. Changes in the rate of excretion can cause unwanted effects. * Gab...'

{{Drugcombi
| base = lithium
| add = gabapentin
| info =
* Lithium is eliminated by the kidney for about 95%. Changes in the rate of excretion can cause unwanted effects.
* Gabapentine is eliminated unchanged by the kidney for 100%.
* This combination of drugs may have possible synergistic effects. There are no reports for pharmacokinetic drug interactions. However, the combination will have additional side effects. <ref name=”freeman”> {{Pubmed|9433333|Freeman et al. Mood stabilizer Combinations: A Review of Safety and Efficacy. Am J Psychiatry 1998;155:12-21}}</ref>
| start =
* Start gabapentine according to the general dosing advice.
| cave =
* Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects. <ref name="drugscom">
{{Drugscominteract|lithium-with-gabapentin|lithium|gabapentin}}</ref>
}}

Combining-Gabapentin-Quetiapine

2010-03-09T23:03:21Z

Klaas: Created page with '{{Drugcombi | base = gabapentin | add = quetiapine | info = * Gabapentine is eliminated unchanged by the kidney for 100%. * Quetiapine is principally metabolized by CYP3A4 to ac...'

{{Drugcombi
| base = gabapentin
| add = quetiapine
| info =
* Gabapentine is eliminated unchanged by the kidney for 100%.
* Quetiapine is principally metabolized by CYP3A4 to active and inactive metabolites.
* This combination of drugs may have possible synergistic effects. There are no reports for pharmacokinetic drug interactions. However, the combination will have additional side effects. <ref name=”freeman”> {{Pubmed|9433333|Freeman et al. Mood stabilizer Combinations: A Review of Safety and Efficacy. Am J Psychiatry 1998;155:12-21}}</ref>
| start =
* Start quetiapine according to the general dosing advice.
| cave =
* Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects. <ref name="drugscom">
{{Drugscominteract|quetiapine-with-gabapentin-1147-0-1979-1274|quetiapine|gabapentin}}</ref>
}}

Combining-Gabapentin-Olanzapine

2010-03-09T23:02:33Z

Klaas: Created page with '{{Drugcombi | base = gabapentin | add = olanzapine | info = * Gabapentine is eliminated unchanged by the kidney for 100%. * Olanzapine is principally metabolized by CYP1A2 and C...'

{{Drugcombi
| base = gabapentin
| add = olanzapine
| info =
* Gabapentine is eliminated unchanged by the kidney for 100%.
* Olanzapine is principally metabolized by CYP1A2 and CYP2D6.
* This combination of drugs may have possible synergistic effects. There are no reports for pharmacokinetic drug interactions. However, the combination will have additional side effects. <ref name=”freeman”> {{Pubmed|9433333|Freeman et al. Mood stabilizer Combinations: A Review of Safety and Efficacy. Am J Psychiatry 1998;155:12-21}}</ref>
| start =
* Start olanzapine according to the general dosing advice.
| cave =
* Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects. <ref name="drugscom">
{{Drugscominteract|olanzapine-with-gabapentin-1147-0-1744-1113|olanzapine|gabapentin}}</ref>
}}

Combining-Gabapentin-Risperidone

2010-03-09T23:01:42Z

Klaas: Created page with '{{Drugcombi | base = gabapentin | add = risperidone | info = * Gabapentine is eliminated unchanged by the kidney for 100%. * Risperidone is principally metabolized by CYP2D6 to ...'

{{Drugcombi
| base = gabapentin
| add = risperidone
| info =
* Gabapentine is eliminated unchanged by the kidney for 100%.
* Risperidone is principally metabolized by CYP2D6 to an active metabolite.
* This combination of drugs may have possible synergistic effects. There are no reports for pharmacokinetic drug interactions. However, the combination will have additional side effects. <ref name=”freeman”> {{Pubmed|9433333|Freeman et al. Mood stabilizer Combinations: A Review of Safety and Efficacy. Am J Psychiatry 1998;155:12-21}}</ref>
| start =
* Start risperidone according to the general dosing advice.
| cave =
* Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects. <ref name="drugscom">
{{Drugscominteract|risperidone-with-gabapentin|risperidone|gabapentin}}</ref>
}}

Combining-Risperidone-Gabapentin

2010-03-09T23:00:08Z

Klaas: Created page with '{{Drugcombi | base = risperidone | add = gabapentin | info = * Risperidone is principally metabolized by CYP2D6 to an active metabolite. * Gabapentine is eliminated unchanged b...'

{{Drugcombi
| base = risperidone
| add = gabapentin
| info =
* Risperidone is principally metabolized by CYP2D6 to an active metabolite.
* Gabapentine is eliminated unchanged by the kidney for 100%.
* This combination of drugs may have possible synergistic effects. There are no reports for pharmacokinetic drug interactions. However, the combination will have additional side effects. <ref name=”freeman”> {{Pubmed|9433333|Freeman et al. Mood stabilizer Combinations: A Review of Safety and Efficacy. Am J Psychiatry 1998;155:12-21}}</ref>
| start =
* Start gabapentine according to the general dosing advice.
| cave =
* Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects. <ref name="drugscom">
{{Drugscominteract|risperidone-with-gabapentin|risperidone|gabapentin}}</ref>
}}

Combining-Quetiapine-Gabapentin

2010-03-09T22:58:11Z

Klaas:

{{Drugcombi
| base = quetiapine
| add = gabapentin
| info =
* Quetiapine is principally metabolized by CYP3A4 to active and inactive metabolites.
* Gabapentine is eliminated unchanged by the kidney for 100%.
* This combination of drugs may have possible synergistic effects. There are no reports for pharmacokinetic drug interactions. However, the combination will have additional side effects. <ref name=”freeman”> {{Pubmed|9433333|Freeman et al. Mood stabilizer Combinations: A Review of Safety and Efficacy. Am J Psychiatry 1998;155:12-21}}</ref>
| start =
* Start gabapentine according to the general dosing advice.
| cave =
* Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects. <ref name="drugscom">
{{Drugscominteract|quetiapine-with-gabapentin-1147-0-1979-1274|quetiapine|gabapentin}}</ref>
}}

Combining-Quetiapine-Gabapentin

2010-03-09T22:57:49Z

Klaas:

{{Drugcombi
| base = quetiapine
| add = gabapentin
| info =
* Quetiapine is principally metabolized by CYP3A4 to active and inactive metabolites.
* Gabapentine is eliminated unchanged by the kidney for 100%.
* This combination of drugs may have possible synergistic effects. There are no reports for pharmacokinetic drug interactions. However, the combination will have additional side effects. <ref name=”freeman”> {{Pubmed|9433333|Freeman et al. Mood stabilizer Combinations: A Review of Safety and Efficacy. Am J Psychiatry 1998;155:12-21}}</ref>
| start =
* Start gabapentine according to the general dosing advice.
| cave =
* Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects. <ref name="drugscom">
{{Drugscominteract|quetiapine-with-gabapentin|quetiapine|gabapentin}}</ref>
}}

Combining-Olanzapine-Gabapentin

2010-03-09T22:57:23Z

Klaas:

{{Drugcombi
| base = olanzapine
| add = gabapentin
| info =
* Olanzapine is principally metabolized by CYP1A2 and CYP2D6.
* Gabapentine is eliminated unchanged by the kidney for 100%.
* This combination of drugs may have possible synergistic effects. There are no reports for pharmacokinetic drug interactions. However, the combination will have additional side effects. <ref name=”freeman”> {{Pubmed|9433333|Freeman et al. Mood stabilizer Combinations: A Review of Safety and Efficacy. Am J Psychiatry 1998;155:12-21}}</ref>
| start =
* Start gabapentine according to the general dosing advice.
| cave =
* Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects. <ref name="drugscom">
{{Drugscominteract|olanzapine-with-gabapentin-1147-0-1744-1113|olanzapine|gabapentin}}</ref>
}}

Combining-Olanzapine-Gabapentin

2010-03-09T22:56:51Z

Klaas:

{{Drugcombi
| base = olanzapine
| add = gabapentin
| info =
* Olanzapine is principally metabolized by CYP1A2 and CYP2D6.
* Gabapentine is eliminated unchanged by the kidney for 100%.
* This combination of drugs may have possible synergistic effects. There are no reports for pharmacokinetic drug interactions. However, the combination will have additional side effects. <ref name=”freeman”> {{Pubmed|9433333|Freeman et al. Mood stabilizer Combinations: A Review of Safety and Efficacy. Am J Psychiatry 1998;155:12-21}}</ref>
| start =
* Start gabapentine according to the general dosing advice.
| cave =
* Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects. <ref name="drugscom">
{{Drugscominteract|olanzapine-with-gabapentin|olanzapine|gabapentin}}</ref>
}}

Combining-Olanzapine-Gabapentin

2010-03-09T22:56:30Z

Klaas: Created page with '{{Drugcombi | base = olanzapine | add = gabapentin | info = * Olanzapine is principally metabolized by CYP1A2 and CYP2D6. * Gabapentine is eliminated unchanged by the kidney fo...'

{{Drugcombi
| base = olanzapine
| add = gabapentin
| info =
* Olanzapine is principally metabolized by CYP1A2 and CYP2D6.
* Gabapentine is eliminated unchanged by the kidney for 100%.
* This combination of drugs may have possible synergistic effects. There are no reports for pharmacokinetic drug interactions. However, the combination will have additional side effects. <ref name=”freeman”> {{Pubmed|9433333|Freeman et al. Mood stabilizer Combinations: A Review of Safety and Efficacy. Am J Psychiatry 1998;155:12-21}}</ref>
| start =
* Start gabapentine according to the general dosing advice.
| cave =
* Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects. <ref name="drugscom">
{{Drugscominteract|olanzapine-with-gabapentine|olanzapine|gabapentine}}</ref>
}}

Combining-Quetiapine-Gabapentin

2010-03-09T22:54:54Z

Klaas: Created page with '{{Drugcombi | base = quetiapine | add = gabapentin | info = * Quetiapine is principally metabolized by CYP3A4 to active and inactive metabolites. * Gabapentine is eliminated u...'

{{Drugcombi
| base = quetiapine
| add = gabapentin
| info =
* Quetiapine is principally metabolized by CYP3A4 to active and inactive metabolites.
* Gabapentine is eliminated unchanged by the kidney for 100%.
* This combination of drugs may have possible synergistic effects. There are no reports for pharmacokinetic drug interactions. However, the combination will have additional side effects. <ref name=”freeman”> {{Pubmed|9433333|Freeman et al. Mood stabilizer Combinations: A Review of Safety and Efficacy. Am J Psychiatry 1998;155:12-21}}</ref>
| start =
* Start gabapentine according to the general dosing advice.
| cave =
* Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects. <ref name="drugscom">
{{Drugscominteract|carbamazepine-with-gabapentine|carbamazepine|gabapentine}}</ref>
}}

Combining-Gabapentin-Carbamazepine

2010-03-09T22:53:45Z

Klaas:

{{Drugcombi
| base = gabapentin
| add = carbamazepine
| info =
* Gabapentine is eliminated unchanged by the kidney for 100%.
* Carbamazepine is principally metabolized by CYP3A4 (also CYP2C8), but is also a potent inducer of CYP1A2, CYP3A4 and UDP-glucuronosyltransferases.
* This combination of drugs may have possible synergistic effects. There are no reports for pharmacokinetic drug interactions. However, the combination will have additional side effects. <ref name=”freeman”> {{Pubmed|9433333|Freeman et al. Mood stabilizer Combinations: A Review of Safety and Efficacy. Am J Psychiatry 1998;155:12-21}}</ref>
| start =
* Start carbamazepine according to the general dosing advice.
| cave =
* Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects. <ref name="drugscom">
{{Drugscominteract|carbamazepine-with-gabapentine|carbamazepine|gabapentine}}</ref>
}}

Combining-Carbamazepine-Gabapentin

2010-03-09T22:53:27Z

Klaas:

{{Drugcombi
| base = carbamazepine
| add = gabapentin
| info =
* Carbamazepine is principally metabolized by CYP3A4 (also CYP2C8), but is also a potent inducer of CYP1A2, CYP3A4 and UDP-glucuronosyltransferases.
* Gabapentine is eliminated unchanged by the kidney for 100%.
* This combination of drugs may have possible synergistic effects. There are no reports for pharmacokinetic drug interactions. However, the combination will have additional side effects. <ref name=”freeman”> {{Pubmed|9433333|Freeman et al. Mood stabilizer Combinations: A Review of Safety and Efficacy. Am J Psychiatry 1998;155:12-21}}</ref>
| start =
* Start gabapentine according to the general dosing advice.
| cave =
* Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects. <ref name="drugscom">
{{Drugscominteract|carbamazepine-with-gabapentine|carbamazepine|gabapentine}}</ref>
}}

Combining-Gabapentin-Valproic acid

2010-03-09T22:52:44Z

Klaas: Created page with '{{Drugcombi | base = gabapentin | add = valproic acid | info = * Gabapentine is eliminated unchanged by the kidney for 100%. Changes in the rate of excretion can cause unwanted ...'

{{Drugcombi
| base = gabapentin
| add = valproic acid
| info =
* Gabapentine is eliminated unchanged by the kidney for 100%. Changes in the rate of excretion can cause unwanted effects.
* Valproic acid is principally metabolized by CYP2C9, CYP2C19, CYP2A6 and UDP-glucuronosyltransferases. Valproic acid is an inhibitor of the enzymes CYP2C9, epoxide-hydroxylase and UDP-glucuronosyltransferases.
* This combination of drugs may have possible synergistic effects. There are no reports for pharmacokinetic drug interactions. However, the combination will have additional side effects.
| start =
* Start valproic acid according to the general dosing advice.
| cave =
}}

Combining-Valproic acid-Gabapentin

2010-03-09T22:51:52Z

Klaas: Created page with '{{Drugcombi | base = valproic acid | add = gabapentin | info = * Valproic acid is principally metabolized by CYP2C9, CYP2C19, CYP2A6 and UDP-glucuronosyltransferases. Valproic a...'

{{Drugcombi
| base = valproic acid
| add = gabapentin
| info =
* Valproic acid is principally metabolized by CYP2C9, CYP2C19, CYP2A6 and UDP-glucuronosyltransferases. Valproic acid is an inhibitor of the enzymes CYP2C9, epoxide-hydroxylase and UDP-glucuronosyltransferases.
* Gabapentine is eliminated unchanged by the kidney for 100%. Changes in the rate of excretion can cause unwanted effects.
* This combination of drugs may have possible synergistic effects. There are no reports for pharmacokinetic drug interactions. However, the combination will have additional side effects.
| start =
* Start gabapentin according to the general dosing advice.
| cave =
}}

Combining-Gabapentin-Carbamazepine

2010-03-09T19:08:38Z

Klaas: Created page with '{{Drugcombi | base = gabapentine | add = carbamazepine | info = ` * Gabapentine is eliminated unchanged by the kidney for 100%. * Carbamazepine is principally metabolized by CYP3...'

{{Drugcombi
| base = gabapentine
| add = carbamazepine
| info = `
* Gabapentine is eliminated unchanged by the kidney for 100%.
* Carbamazepine is principally metabolized by CYP3A4 (also CYP2C8), but is also a potent inducer of CYP1A2, CYP3A4 and UDP-glucuronosyltransferases.
* This combination of drugs may have possible synergistic effects. There are no reports for pharmacokinetic drug interactions. <ref name=”freeman”> {{Pubmed|9433333|Freeman et al. Mood stabilizer Combinations: A Review of Safety and Efficacy. Am J Psychiatry 1998;155:12-21}}</ref>
| start =
* Start carbamazepine according to the general dosing advice.
| cave =
* Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects. <ref name="drugscom">
{{Drugscominteract|carbamazepine-with-gabapentine|carbamazepine|gabapentine}}</ref>
}}

Combining-Carbamazepine-Gabapentin

2010-03-09T19:07:31Z

Klaas: Created page with '{{Drugcombi | base = carbamazepine | add = gabapentine | info = * Carbamazepine is principally metabolized by CYP3A4 (also CYP2C8), but is also a potent inducer of CYP1A2, CYP3A...'

{{Drugcombi
| base = carbamazepine
| add = gabapentine
| info =
* Carbamazepine is principally metabolized by CYP3A4 (also CYP2C8), but is also a potent inducer of CYP1A2, CYP3A4 and UDP-glucuronosyltransferases.
* Gabapentine is eliminated unchanged by the kidney for 100%.
* This combination of drugs may have possible synergistic effects. There are no reports for pharmacokinetic drug interactions. <ref name=”freeman”> {{Pubmed|9433333|Freeman et al. Mood stabilizer Combinations: A Review of Safety and Efficacy. Am J Psychiatry 1998;155:12-21}}</ref>
| start =
* Start gabapentine according to the general dosing advice.
| cave =
* Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects. <ref name="drugscom">
{{Drugscominteract|carbamazepine-with-gabapentine|carbamazepine|gabapentine}}</ref>
}}

Combining-Quetiapine-Valproic acid

2010-03-09T18:57:12Z

Klaas:

{{Drugcombi
| base = quetiapine
| add = valproic acid
| info =
* Quetiapine is principally metabolized by CYP3A4 to active and inactive metabolites.
* Valproic acid is principally metabolized by CYP2C9, CYP2C19, CYP2A6 and UDP-glucuronosyltransferases. Valproic acid is an inhibitor of the enzymes CYP2C9, epoxide-hydroxylase and UDP-glucuronosyltransferases.
* This combination of drugs may have possible synergistic effects. However, this combination will also have additive side effects. Dose adaptation will be recommended for this combination. <ref> {{Pubmed|18579216|Vieta E at al, Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord. 2008 Aug;109(3):251-63. Epub 2008 Jun 24}}</ref>
| start =
* Start valproic acid according to the general dosing advice.
| cave =
* During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. <ref name="drugscom">
{{Drugscominteract|quetiapine-with-valproic-acid-1979-1274-2286-0|quetiapine|valproic acid}}</ref>
}}

Combining-Topiramate-Quetiapine

2010-03-09T18:55:05Z

Klaas:

{{Drugcombi
| base = topiramate
| add = quetiapine
| info =
* Topiramate induces CYP3A4 and is an inhibitor of CYP2C19.
* Quetiapine is principally metabolized by CYP3A4 to active and inactive metabolites.
* This combination of drugs may have possible synergistic effects. However, this combination will also have additive side effects. Dose adaptation will be recommended for this combination.
| start =
* Start quetiapine according general dosing advice.
| cave =
* Caution is advised when topiramate is prescribed with other drugs that predispose patients to heat-related disorders, including carbonic anhydrase inhibitors and drugs with anticholinergic activity. <ref name="drugscom">
{{Drugscominteract|quetiapine-with-topiramate-1979-1274-2216-1469|quetiapine|topiramate}}</ref>
}}

Combining-Quetiapine-Topiramate

2010-03-09T18:54:51Z

Klaas:

{{Drugcombi
| base = quetiapine
| add = topiramate
| info =
* Quetiapine is principally metabolized by CYP3A4 to active and inactive metabolites.
* Topiramate induces CYP3A4 and is an inhibitor of CYP2C19.
* This combination of drugs may have possible synergistic effects. However, this combination will also have additive side effects. Dose adaptation will be recommended for this combination.
| start =
* Start topiramate according general dosing advice.
| cave =
* Caution is advised when topiramate is prescribed with other drugs that predispose patients to heat-related disorders, including carbonic anhydrase inhibitors and drugs with anticholinergic activity. <ref name="drugscom">
{{Drugscominteract|quetiapine-with-topiramate-1979-1274-2216-1469|quetiapine|topiramate}}</ref>
}}

Combining-Quetiapine-Topiramate

2010-03-09T18:54:12Z

Klaas: Created page with '{{Drugcombi | base = quetiapine | add = topiramate | info = * Quetiapine is principally metabolized by CYP3A4 to active and inactive metabolites. * Topiramate induces CYP3A4 an...'

Combining-Quetiapine-Lithium

2010-03-09T18:51:19Z

Klaas:

{{Drugcombi
| base =
| add = quetiapine
| info = lithium
* Quetiapine is principally metabolized by CYP3A4 to active and inactive metabolites.
* Lithium is eliminated by the kidney for about 95%. Changes in the rate of excretion can cause unwanted effects.
* This combination of drugs may have possible synergistic effects. However, this combination will also have additive side effects. Dose adaptation will be recommended for this combination. <ref> {{Pubmed|18579216|Vieta E at al, Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord. 2008 Aug;109(3):251-63. Epub 2008 Jun 24}}</ref>
| start =
* Start lithium according to the general dosing advice.
| cave =
* During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. <ref name="drugscom">
{{Drugscominteract|quetiapine-with-lithium/1477-0-1979-1274|quetiapine|lithium}}</ref>
}}

Combining-Lithium-Quetiapine

2010-03-09T18:51:10Z

Klaas:

{{Drugcombi
| base = lithium
| add = quetiapine
| info =
* Lithium is eliminated by the kidney for about 95%. Changes in the rate of excretion can cause unwanted effects.
* Quetiapine is principally metabolized by CYP3A4 to active and inactive metabolites.
* This combination of drugs may have possible synergistic effects. However, this combination will also have additive side effects. Dose adaptation will be recommended for this combination. <ref> {{Pubmed|18579216|Vieta E at al, Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord. 2008 Aug;109(3):251-63. Epub 2008 Jun 24}}</ref>
| start =
* Start quetiapine according to the general dosing advice.
| cave =
* During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. <ref name="drugscom">
{{Drugscominteract|quetiapine-with-lithium/1477-0-1979-1274|quetiapine|lithium}}</ref>
}}

Combining-Quetiapine-Lithium

2010-03-09T18:50:21Z

Klaas:

Combining-Quetiapine-Lamotrigine

2010-03-09T18:47:53Z

Klaas: Created page with '{{Drugcombi | base = quetiapine | add = lamotrigine | info = * Quetiapine is principally metabolized by CYP3A4 to active and inactive metabolites. * Lamoptrigine is principally...'

{{Drugcombi
| base = quetiapine
| add = lamotrigine
| info =
* Quetiapine is principally metabolized by CYP3A4 to active and inactive metabolites.
* Lamoptrigine is principally metabolised by UDP-glucuronosyltransferases.
* This combination of drugs may have possible synergistic effects. However, this combination will also have additive side effects. Dose adaptation will be recommended for this combination.
| start =
* Start lamotrigine according to the general dosing advice.
| cave =
}}

Combining-Carbamazepine-Quetiapine

2010-03-09T18:46:08Z

Klaas:

{{Drugcombi
| base = carbamazepine
| add = quetiapine
| info =
* Carbamazepine is principally metabolized by CYP3A4 (also CYP2C8), but is also a potent inducer of CYP1A2, CYP3A4 and UDP-glucuronosyltransferases.
* Quetiapine is principally metabolized by CYP3A4 to active and inactive metabolites.
* This combination of drugs may have possible synergistic effects. However, this combination will also have additive side effects. Dose adaptation will be recommended for this combination.
| start =
* Carbamazepine can reduce quetiapine serum concentration, possible below therapeutic range. <ref> {{Pubmed|15385830|Hasselstrom and Linnet, Quetiapine serum concentrations in psychiatric patients: the influence of comedication. Ther Drug Monit 2004;26:486-91}}</ref>
* Add quetiapine according to the general dosing advice and increase dose based on clinical effect or serum concentration. <ref name=”medicatiebewaking”> Schalekamp T. et al, Interacties met Psychofarmaca, Stichting Health Base, Houten, 2002. </ref> <ref name=”bazire”> Bazire S, Psychotropic Drug Directory 2007, HealthComm UK Limited, Aberdeen, 2007. </ref>
| cave =
}}

Combining-Quetiapine-Carbamazepine

2010-03-09T18:46:06Z

Klaas: Created page with '{{Drugcombi | base = quetiapine | add = carbamazepine | info = * Quetiapine is principally metabolized by CYP3A4 to active and inactive metabolites. * Carbamazepine is principa...'

{{Drugcombi
| base = quetiapine
| add = carbamazepine
| info =
* Quetiapine is principally metabolized by CYP3A4 to active and inactive metabolites.
* Carbamazepine is principally metabolized by CYP3A4 (also CYP2C8), but is also a potent inducer of CYP1A2, CYP3A4 and UDP-glucuronosyltransferases.
* This combination of drugs may have possible synergistic effects. However, this combination will also have additive side effects. Dose adaptation will be recommended for this combination.
| start =
* Start carbamazepine according to the general dosing advice.
* The pharmacologic response to quetiapine should be monitored more closely. Dose adoptation of quetiapine could be necessary.
| cave =
* Carbamazepine can reduce quetiapine serum concentration, possible below therapeutic range. <ref> {{Pubmed|15385830|Hasselstrom and Linnet, Quetiapine serum concentrations in psychiatric patients: the influence of comedication. Ther Drug Monit 2004;26:486-91}}</ref>
}}

Combining-Olanzapine-Quetiapine

2010-03-09T18:36:34Z

Klaas:

{{Drugcombi
| base = olanzapine
| add = quetiapine
| info =
* Olanzapine is principally metabolized by CYP1A2 and CYP2D6.
* Quetiapine is principally metabolized by CYP3A4 to active and inactive metabolites.
* This combination of drugs may have possible synergistic effects. However, this combination will also have additive side effects. Dose adaptation will be recommended for this combination.
| start =
* Start quetiapine according to the general dosing advice.
| cave =
* Agents with anticholinergic properties may have additive effects when used in combination. <ref name="drugscom">
{{Drugscominteract|olanzapine-with-quetiapine-1979-1274-1744-1113|olanzapine|quetiapine}}</ref>
}}

Combining-Quetiapine-Olanzapine

2010-03-09T18:36:33Z

Klaas: Created page with '{{Drugcombi | base = quetiapine | add = olanzapine | info = * Quetiapine is principally metabolized by CYP3A4 to active and inactive metabolites. * Olanzapine is principally me...'

{{Drugcombi
| base = quetiapine
| add = olanzapine
| info =
* Quetiapine is principally metabolized by CYP3A4 to active and inactive metabolites.
* Olanzapine is principally metabolized by CYP1A2 and CYP2D6.
* This combination of drugs may have possible synergistic effects. However, this combination will also have additive side effects. Dose adaptation will be recommended for this combination.
| start =
* Start olanzapine according to the general dosing advice.
| cave =
* Agents with anticholinergic properties may have additive effects when used in combination. <ref name="drugscom">
{{Drugscominteract|olanzapine-with-quetiapine-1979-1274-1744-1113|olanzapine|quetiapine}}</ref>
}}

Combining-Olanzapine-Quetiapine

2010-03-09T18:35:21Z

Klaas: Created page with '{{Drugcombi | base = olanzapine | add = quetiapine | info = * Olanzapine is principally metabolized by CYP1A2 and CYP2D6. * Quetiapine is principally metabolized by CYP3A4 to a...'

Combining-Olanzapine-Valproic acid

2010-03-09T18:31:22Z

Klaas: Created page with '{{Drugcombi | base = olanzapine | add = valproic acid | info = * Olanzapine is principally metabolized by CYP1A2 and CYP2D6. * Valproic acid is principally metabolized by CYP2C9...'

{{Drugcombi
| base = olanzapine
| add = valproic acid
| info =
* Olanzapine is principally metabolized by CYP1A2 and CYP2D6.
* Valproic acid is principally metabolized by CYP2C9, CYP2C19, CYP2A6 and UDP-glucuronosyltransferases. Valproic acid is an inhibitor of the enzymes CYP2C9, epoxide-hydroxylase and UDP-glucuronosyltransferases.
* This combination of drugs may have possible synergistic effects. However, this combination will also have additive side effects. Dose adaptation will be recommended for this combination.
| start =
* Start valproic acid according to the general dosing advice. Monitoring of the liver function every 3 to 4 months during the first year of treatment with either olanzapine or valproic acid is recommended.<ref name="drugscom">
{{Drugscominteract|olanzapine-with-valproic-acid-1744-0-2286-0|olanzapine|valproic acid}}</ref>
| cave =
* Concurrent use of olanzapine and valproic acid may potentiate the risk of hepatotoxicity.<ref name="drugscom" />
}}

Combining-Valproic acid-Olanzapine

2010-03-09T18:31:06Z

Klaas:

{{Drugcombi
| base = valproic acid
| add = olanzapine
| info =
* Valproic acid is principally metabolized by CYP2C9, CYP2C19, CYP2A6 and UDP-glucuronosyltransferases. Valproic acid is an inhibitor of the enzymes CYP2C9, epoxide-hydroxylase and UDP-glucuronosyltransferases.
* Olanzapine is principally metabolized by CYP1A2 and CYP2D6.
* This combination of drugs may have possible synergistic effects. However, this combination will also have additive side effects. Dose adaptation will be recommended for this combination.
| start =
* Start olanzapine according to the general dosing advice. Monitoring of the liver function every 3 to 4 months during the first year of treatment with either olanzapine or valproic acid is recommended.<ref name="drugscom">
{{Drugscominteract|olanzapine-with-valproic-acid-1744-0-2286-0|olanzapine|valproic acid}}</ref>
| cave =
* Concurrent use of olanzapine and valproic acid may potentiate the risk of hepatotoxicity.<ref name="drugscom" />
}}

Combining-Topiramate-Olanzapine

2010-03-09T18:29:25Z

Klaas:

{{Drugcombi
| base = topiramate
| add = olanzapine
| info =
* Topiramate induces CYP3A4 and is an inhibitor of CYP2C19.
* Olanzapine is principally metabolized by CYP1A2 and CYP2D6.
* This combination of drugs may have possible synergistic effects. However, this combination will also have additive side effects. Dose adaptation will be recommended for this combination.
| start =
* Start olanzapine according general dosing advice.
| cave =
* Caution is advised when topiramate is prescribed with other drugs that predispose patients to heat-related disorders, including carbonic anhydrase inhibitors and drugs with anticholinergic activity. <ref name="drugscom">
{{Drugscominteract|olanzapine-with-topiramate-1116-1111-2216-1469|olanzapine|topiramate}}</ref>
}}

Combining-Olanzapine-Topiramate

2010-03-09T18:29:02Z

Klaas:

{{Drugcombi
| base = olanzapine
| add = topiramate
| info =
* Olanzapine is principally metabolized by CYP1A2 and CYP2D6.
* Topiramate induces CYP3A4 and is an inhibitor of CYP2C19.
* This combination of drugs may have possible synergistic effects. However, this combination will also have additive side effects. Dose adaptation will be recommended for this combination.
| start =
* Start topiramate according general dosing advice.
| cave =
* Caution is advised when topiramate is prescribed with other drugs that predispose patients to heat-related disorders, including carbonic anhydrase inhibitors and drugs with anticholinergic activity. <ref name="drugscom">
{{Drugscominteract|olanzapine-with-topiramate-1116-1111-2216-1469|olanzapine|topiramate}}</ref>
}}

Combining-Olanzapine-Topiramate

2010-03-09T18:28:32Z

Klaas: Created page with '{{Drugcombi | base = olanzapine | add = topiramate | info = * Olanzapine is principally metabolized by CYP1A2 and CYP2D6. * Topiramate induces CYP3A4 and is an inhibitor of CYP2...'

Combining-Olanzapine-Lithium

2010-03-09T18:25:41Z

Klaas:

{{Drugcombi
| base = olanzapine
| add = lithium
| info =
* Olanzapine is principally metabolized by CYP1A2 and CYP2D6.
* Lithium is eliminated by the kidney for about 95%. Changes in the rate of excretion can cause unwanted effects.
* This combination of drugs may have possible synergistic effects. However, this combination will also have additive side effects. Dose adaptation will be recommended for this combination.
| start =
* Start lithium according to the general dosing advice.
| cave =
* The concomitant administration of lithium with neuroleptic agents may increase the risk of extrapyramidal reactions and neurotoxicity. <ref name="drugscom">
{{Drugscominteract|olanzapine-with-lithium-1477-0-1744-1113|olanzapine|lithium}}</ref>
}}

Combining-Olanzapine-Lithium

2010-03-09T18:25:00Z

Klaas: Created page with '{{Drugcombi | base = olanzapine | add = lithium | info = * Olanzapine is principally metabolized by CYP1A2 and CYP2D6. * Lithium is eliminated by the kidney for about 95%. Chang...'